Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syros Pharmaceuticals, Inc. - Common Stock
(NQ:
SYRS
)
0.1172
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syros Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?
December 06, 2023
Syros Pharmaceuticals Inc (NASDAQ: SYRS) released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in combination with venetoclax and azacitidine in newly diagnosed, unfit...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 06, 2023
Via
Benzinga
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
December 06, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
December 03, 2023
Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.
Via
InvestorPlace
Preview: Syros Pharmaceuticals's Earnings
November 13, 2023
Via
Benzinga
Earnings Outlook For Syros Pharmaceuticals
August 07, 2023
Via
Benzinga
Syros Pharmaceuticals: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
Syros Pharmaceuticals's Earnings Outlook
May 09, 2023
Via
Benzinga
Syros to Participate in Upcoming Investor Conferences
November 21, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 14, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
October 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 02, 2023
Via
Benzinga
Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
October 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2023
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
August 11, 2023
Via
Benzinga
Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
August 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood Disorders
July 24, 2023
Syros Pharmaceuticals Inc received notice from Pfizer Inc (NYSE: PFE), as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated...
Via
Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Sidoti Events, LLC's Virtual June Small-Cap Conference
June 13, 2023
Via
ACCESSWIRE
Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
June 08, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
May 25, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 10, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Present at JMP Securities 2023 Life Sciences Conference
May 09, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
May 03, 2023
From
Syros Pharmaceuticals
Via
Business Wire
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Syros Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 04, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
